首页|The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment:a systematic review

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment:a systematic review

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Aim:Cancer as a complex disease poses significant challenges for both diagnosis and treatment.Researchers have been exploring various avenues to find effective therapeutic strategies,with a particular emphasis on cellular signaling pathways and immunotherapy.One such pathway that has recently been suggested is the PD-1/PD-L1 pathway,which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis.Cancer cells exploit this pathway by producing PD-L1,which attaches to PD-1 on T cells,thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system.This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment.Method:This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis(PRISMA).All in vitro,in vivo,and clinical studies that were published in English have been considered during a thorough search of the Scopus,Web of Science,and PubMed databases without date restriction until March 2024.Results:According to the studies reviewed,the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer,melanoma,breast cancer,hepatocellular carcinoma,squamous cell carcinoma,and colorectal cancer,among others.Additionally,research suggests that immune checkpoint inhibitors that block PD1/PD-L1,such as pembrolizumab,atezolizumab,nivolumab,durvalumab,cemiplimab,avelumab,etc.,can effectively prevent tumor cells from escaping the immune system.Moreover,there might be a possible interaction between microbiome,obesity,etc.on immune mechanisms and on the immune checkpoint inhibitors(ICIs).Conclusion:Although we have gained considerable knowledge about ICIs,we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients.This is largely due to the complex interactions between different intracellular pathways,which need to be thoroughly studied.To resolve this issue,it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

PD-1/PD-L1 pathwaycancerimmunotherapyimmune checkpoint inhibitors

Amirhosein Sabaghian、Shahnam Shamsabadi、Saghar Momeni、Mobina Mohammadikia、Kiarash Mohebbipour、Samira Sanami、Sajjad Ahmad、Nahid Akhtar、Neeta Raj Sharma、Raja Babu Singh Kushwah、Yash Gupta、Ajit Prakash、Hamidreza Pazoki-Toroudi

展开 >

Physiology Research Center&Department of Physiology,Faculty of Medicine,Iran University of Medical Sciences,Tehran,Iran

Abnormal Uterine Bleeding Research Center,Semnan University of Medical Sciences,Semnan,Iran

Department of Health and Biological Sciences,Abasyn University,Peshawar 25000,Pakistan

Gilbert and Rose-Marie Chagoury School of Medicine,Lebanese American University,Beirut P.O.Box 36,Lebanon

Department of Natural Sciences,Lebanese American University,Beirut P.O.Box 36,Lebanon

School of Bioengineering and Biosciences,Lovely Professional University,Phagwara 144411,India

Department of Entomology,Texas A&M University,College Station,TX 77843,USA

Department of Medicine,Penn State College of Medicine,Hershey,PA 17033,USA

Department of Biochemistry and Biophysics,University of North Carolina,Chapel Hill,NC 27599,USA

展开 >

2024

10.20517/2394-4722.2024.15

癌症转移与治疗(英文版)

癌症转移与治疗(英文版)

ISSN：
年,卷(期)：2024.10(5)
  • 1